Adaptimmune Therapeutics PLC reports results for the quarter ended in March - Earnings Summary

Adaptimmune Therapeutics

12/05/2023 15:58

* Adaptimmune Therapeutics PLC  ADAP.OQ  reported quarterly
adjusted earnings of 1 cent​​ per share for the quarter ended in
March. The mean expectation of eight analysts for the quarter
was for a loss of 15 cents per share.
    * Revenue rose 1,231.5% to $47.60 million from a year ago;
analysts expected $4.93 million. 
    * Adaptimmune Therapeutics PLC's reported EPS for the
quarter was
1 cent​.
    * The mean earnings estimate of analysts had risen by
about 33.9%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Adaptimmune Therapeutics PLC shares had risen by 24.8%
this
quarter and lost 6.8% so far this year.
    * The company reported quarterly net income of $1.04
million.
    * Wall Street's median 12-month price target for Adaptimmune
Therapeutics PLC is $4.30 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
12 at 02:58 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.15          0.01           Beat
 Dec. 31 2022      -0.25          -0.18          Beat
 Sep. 30 2022      -0.24          -0.24          Met
 Jun. 30 2022      -0.25          -0.28          Missed